Mdxhealth’s molecular diagnostic solutions address a significant unmet medical need for timely, actionable information that addresses the challenges of the current standard of care for diagnosing and treating prostate cancer. Our tests identify patients at increased risk for aggressive prostate cancer, aiding in the selection of at-risk men for prostate biopsy, as well as in the selection of newly-diagnosed men for appropriate treatment.
A highly predictive urine test to help identify men at risk for aggressive prostate cancer prior to initial biopsy.
A tissue test to improve the identification of men at risk for undetected clinically significant prostate cancer after a negative biopsy.
Localized Prostate Cancer
A genomic assay designed for men with low-, intermediate-, and high-risk localized prostate cancer to help guide treatment decisions at the time of diagnosis.
Urinary Tract Infection (UTI)
The advanced UTI testing solution that quickly provides personalized therapy options
Science & Technology
Mdxhealth has a proprietary portfolio of biomarkers and bioinformatic technologies from which it develops and commercializes state-of-the-art diagnostic, prognostic and predictive tests for urologic oncology.